

As an educational provider accredited by the ACCME, the ACR must ensure balanced, independent, objectively and scientific rigor in all its educational activities. The 2010 ACR/ARHP Annual Scientific Meeting programs have been independently planned by the ACR Annual Meeting Planning Committee, the ARHP Annual Meeting Program Committee, and the ARHP Clinical Focus Course Task Force.

## **2010 ACR Annual Meeting Planning Committees Members Disclosures**

---

### **Abby Abelson, MD**

Amgen - speaker's bureau; Novartis - speaker's bureau; Procter and Gamble - speaker's bureau

### **Jennifer H. Anolik, MD, PhD**

Bristol Meyers Squibb - speaker's bureau; Proteolix - research grants; Vaccinex - research grants  
Roche - consulting fees; Genentech - consulting fees; Amgen - consulting fees

### **Joel A. Block, MD**

Merck-Serono - consulting fees; Abbott - consulting fees

### **Robert H. Carter, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

### **Stanley B. Cohen, MD**

HPI Pharma, research grants; Pfizer - stocks, stock options and bond holdings

### **Mary E. Cronin, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

### **Kori Dewing, MN, ARNP**

Virginia Mason - employment; Institute for Continuing Healthcare Education - employment;  
Amgen/Wyeth - speaker's bureau; UCB - speaker's bureau; Arthritis Foundation NW Chapter - non-remunerative position of influence; WAP - non-remunerative position of influence

### **Barbara A. Eberhard, MBBS, MSc**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

### **Keith B. Elkon, MD**

Roche - research grants

### **Polly J. Ferguson, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

### **James G. Freeman, MD**

Takeda – speaker's bureau

**Richard Furie, MD**

BiogenIdec - consulting fees, other; BMS - consulting fees, other; Boehringer-Ingelheim - consulting fees; Cypress Bioscience - consulting fees; Genentech - consulting fees, other; Hoffmann LaRoche - consulting fees, other; Human Genome Sciences - consulting fees, other; Idera - consulting fees; La Jolla Pharmaceutical Co. - other; Medimmune - consulting fees, other; Medarex - consulting fees; NIAID - consulting fees, other; NovoNordisk - consulting fees, other; Nuon - consulting fees; Rigel - consulting fees, other; Roche - consulting fees, other; UCB - consulting fees, other; American College of Rheumatology - non-remunerative position of influence; Arthritis Foundation - non-remunerative position of influence; LFA - non-remunerative position of influence; Lupus Alliance of America - non-remunerative position of influence; NIAMS - non-remunerative position of influence; SLE Foundation - non-remunerative position of influence; Lupus Research Alliance - non-remunerative position of influence

**Gregory Gardner, MD**

Amgen - speaker's bureau

**Steven R. Goldring, MD**

Telik - stocks, stock options or bond holdings; Boehringer Ingelheim - research grants; Bone Therapeutics - consulting fees; Pfizer - consulting fees; Biogen - consulting fees

**Alexei A. Grom, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Bruce I. Hoffman, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Raymond S. Hong, MD**

Novartis - speaker's bureau; Glaxo Smith Kline - speaker's bureau

**Alisa E. Koch, MD**

Guidepoint Global - consulting fees; Cyprus Bioscience, Inc. - consulting fees; Fund for Autoimmune Research - consulting fees; Gerson Lerman Group's Council of Healthcare Advisors - consulting fees; Nicox SA - consulting fees; UCB Pharmaceuticals - consulting fees; Takeda Pharmaceuticals - research grants; Roche Pharmaceuticals - research grants

**Carol Langford, MD, MHS**

Genentech - research grants; Bristol-Myers Squibb - research grants; McGraw Hill Publishing - other

**Nancy Liu, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Richard F. Loeser, Jr., MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Richard J. Looney, MD**

Proteolix - research grants, consulting fees; Genentech/Roche/BiogenIDEC - consulting fees  
NovoNordisk - consulting fees; Centocor - consulting fees; Bristol-Meyers Squibb - consulting fees  
Pfizer - consulting fees; Vaccinex - consulting fees

**Augustine M. Manadan, MD**

UCB - other

**Brian F. Mandell, MD, PhD**

URL - consulting fees; participated in CME-funded lectures; Savient – other (Clinical Investigator); Takeda  
Consultants; participated in CME-funded lecture; Merck - receipt of royalties

**Susan Manzi, MD, MPH**

Human Geonome Sciences - non-remunerative position of influence, other; Bristol-Meyers Squibb Co. -  
non-remunerative position of influence; Centocor, Inc. – other; Cephalon Inc. - consulting fees, other;  
Medimmune Inc. - consulting fees; Cellatope Corp. - consulting fees, other; Cypress Bioscience -  
consulting fees, non-remunerative position of influence, other

**Kevin McKown, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the  
past twelve months.*

**Zsuzsanna McMahan, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the  
past twelve months.*

**Chester V. Oddis, MD**

Genentech - research grants

**Thomas Olenginski, MD**

Wyeth - speaker's bureau; Amgen - speaker's bureau; Novartis - speaker's bureau; P & G - speaker's  
bureau; Sanofi Aventis - speaker's bureau; Roche – other; Forest - speaker's bureau; Eli-Lilly - other

**Kathleen M. O'Neil, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the  
past twelve months.*

**Janet L. Poole, PhD, OTR/L**

*I have not had any relevant commercial relationships with any commercial interest occurring within the  
past twelve months.*

**Christopher Ritchlin, MD, MPH**

Amgen - research grants, consulting fees; Abbott - research grants; Centocor - research grants,  
consulting fees; Pfizer - consulting fees; MorphoSys - consulting fees; Sinolfi - consulting fees; Bristol  
Myers Squibb - consulting fees

**Carlos D. Rose, MD, CIP**

Amgen - speaker's bureau; Department of Health & Human Services - consulting fees; Department of Justice - consulting fees; Glaxo Smith Kline (expected before year end) - research grants; Novartis (negotiation phase) - research grants

**Eric M. Ruderman, MD**

Abbott - research grants, consulting fees; Amgen/Wyeth - consulting fees; UCB - consulting fees; Centocor - research grants; Array - research grants; Targeted Genetics - research grants; Crescendo - research grants; Elan - stocks, stock options or bond holdings; Genzyme Biotechnology - stocks, stock options or bond holdings; Epiphany Healthcare Consultants - other

**Jorge Sanchez-Guerrero, MD, MS**

Amgen - consulting fees; Genentech - consulting fees

**Nan Shen, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Robert Simms, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Robert Spiera, MD**

Novartis - research grants; BMS - research grants; United Therapeutics - research grants

**Paul P. Tak, MD, PhD**

Bristol-Meyers Squibb - research grants; Abbott - consulting fees, speaker's bureau; Roche - research grants, consulting fees, speaker's bureau; Wyeth - research grants, consulting fees, speaker's bureau; Astellas - research grants, consulting fees; Eli Lilly - consulting fees; GSK - research grants, consulting fees; Johnson and Johnson - research grants, consulting fees; Novartis - research grants, consulting fees; Arthrogen - stocks, stock options or bond holdings

**John R.P. Tesser, MD**

Abbott - consulting fees, speaker's bureau; Amgen - consulting fees, speaker's bureau; Biogen Idec - speaker's bureau; Bristol-Meyers Squibb - speaker's bureau; Centocor Ortho Biotech - research grants, consulting fees, speaker's bureau; Genentech - research grants, consulting fees, speaker's bureau; Nuon - research grants; Pfizer - research grants, consulting fees, speaker's bureau; Roche - research grants, consulting fees, speaker's bureau; Takeda - speaker's bureau

**Alexandra Villa-Forte, MD,MPH**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Raymond L. Yung, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

## **2010 ARHP Annual Meeting Program Committee Members Disclosures**

---

**Janet L. Poole, PhD, OTR**

American College of Rheumatology/REF- Research grants

**Kori A. Dewing, MN, ARNP**

Institute for Continuing Healthcare Education - Consulting fees or other remuneration; Amgen/Wyeth and UCB-Speaker's bureau; Arthritis Foundation, NW Chapter, Professional Education Committee and WRAP/WA Rheumatology ARNPs/PAs, outgoing president - Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson

**Atul A. Deodhar, MD**

Centocor and Genentech - Stock options or bind holdings in a for-profit corporation or self-directed pension plan; Consulting fees or other remuneration; Speaker's bureau

**Donna K, Everix, MPA, BS, PT**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Nadine M. Fisher, EdD**

National Institute on Disability and Rehabilitation Research; Blue Cross/Blue Shield of Western New York and National Institute on Disability and Rehabilitation Research - Research grants

**Bernadette McNally, MS, PA-C**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Susan M. Oliver, MSc**

Abbott Laboratories, Roche, Schering Plough and UCB-Consulting fees or other remuneration; Pfizer, UCB and Wyeth - Honoraria for participation in an activity or the use of intellectual property; Musculoskeletal Care Journal, Editorial Board member - Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson

**Elizabeth G. Salt, PhD, ARNP**

American College of Rheumatology/REF - Research grants; SmithKline Beecham - Honoraria for participation in an activity or the use of intellectual property; Fidelity Retirement Account - Stock options or bind holdings in a for-profit corporation or self-directed pension plan

**Emily C. Somers, PhD, ScM**

Baker Bros. Investments - Honoraria for participation in an activity or the use of intellectual property; Centers for Disease Control, National Institutes of Health, Lupus Foundation and National Institutes of Health; Research grants

**Sandra J. Watcher, BSN, RN**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Mary Wright, BS, OT**

Arthritis Foundation, Program Committee member - Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson

**Benjamin H. Smith, PA-C**

Amgen - Consulting fees or other remuneration; Amgen and Wyeth - Speaker's bureau

## **2010 ARHP Clinical Focus Course Task Force Disclosures**

---

**Sandra J. Watcher, BSN, RN**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Joyce M. Kortan, RN**

Centocor - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Amgen, Inc - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Novartis - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Genentech, Inc. - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Biogen, Idec, Inc. - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Bristol Myers Squibb - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; UCB - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Mitsubishi Tanabe Pharma Corporation - Honoraria for participation in an activity or the use of intellectual property, Speaker's bureau; Roche - Honoraria for participation in an activity or the use of intellectual property; The Institute of Continuing Healthcare Education - Honoraria for participation in an activity or the use of intellectual property; Wyeth - Speaker's bureau; and BioCentric, Inc. - Speaker's bureau

**Jessica F. Farrell, PharmD**

Consortium of Rheumatology Researchers of North America (CORRONA) - Honoraria for participation in an activity or the use of intellectual property

**Karen Huisinga, MN, ARNP, FNP**

Amgen -Speaker's bureau; Wyeth - Speaker's bureau; UCB - Speaker's bureau

**Daniel Battafarano, DO**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***